P392 Outcomes after elective withdrawal of anti-TNF therapy in Crohn's disease: a multicentre study

  • Sebastian S
  • Robinson K
  • Warren L
  • et al.
N/ACitations
Citations of this article
5Readers
Mendeley users who have this article in their library.

Abstract

Background: The impact of stopping anti-TNF therapy for patients in apparent clinical and/or endoscopic remission in routine clinical practice setting is uncertain. We aimed to evaluate clinical outcomes in patients who discontinued anti- TNF therapy electively after at least 12 months of therapy across 3 large centres within Yorkshire & Humber IBD Network, UK. Methods: Patients with Crohn's disease, whose anti-TNF therapy (62 Infliximab [IFX], 9 adalimumab [ADA]) was stopped electively following a planned assessment were included. All patients had been treated for at least 12 months and followed for at least 3 months after cessation of anti-TNF therapy. Assessment prior to cessation comprised colonoscopy (n = 52), colon capsule (n = 4), MRE (n = 19), Small bowel capsule (n = 5), barium study (n = 2), and clinical assessment (n = 9). Results: 71 patients with Crohn's disease (44 female; median age at diagnosis 24; median duration of disease prior to anti-TNF therapy 21.5 months) were included. Indication for treatment was severe active luminal (n = 50), fistulating perianal (n = 18) and other fistulating disease (n = 3). The median duration of anti-TNF therapy was 18 months (range 12 78). 62 patients (87.3%) continued on immunomodulator therapy following anti-TNF withdrawal. Relapse rates after 90 days, 180 days and 365 days were 3/71 (4.2%), 5/67 (7.5%), 12/56 (21.4%) respectively. of those with perianal disease, the relapse rate was 6/18 (33%) at 365 days. All 6 patients who had dose escalation in the 6 months before withdrawal relapsed. Twenty-five relapsed patients were retreated with anti-TNF agents (9 ADA; 16 IFX), with a response rate of 80% when retreated with same agent as had been withdrawn. 5 patients where IFX was withdrawn responded when retreated with ADA. The overall recapture of response with use of either agent was 84%. Assessment practice changed after NICE guidance was issued in May 2010; before this 6 of 15 (40%) patients stopping anti-TNF therapy had clinical assessment alone. Only 3 of 56 patients (5.3%) were assessed after that date by clinical assessment alone. Conclusions: Relapse rates following withdrawal of anti- TNF therapy are lower than previously reported, with a high response rate on retreatment. Patients requiring dose escalation in the 6 months prior to withdrawal may be at higher risk of relapse. We have demonstrated increased endoscopic and radiological assessment prior to withdrawal of anti-TNF therapy. Prospective evaluation of a withdrawal and retreatment strategy for anti-TNF treatment in a larger cohort of Crohn's patients is required

Cite

CITATION STYLE

APA

Sebastian, S., Robinson, K., Warren, L., Marsh, A., Wright, A., Majeed, F., … Lobo, A. (2013). P392 Outcomes after elective withdrawal of anti-TNF therapy in Crohn’s disease: a multicentre study. Journal of Crohn’s and Colitis, 7, S166–S167. https://doi.org/10.1016/s1873-9946(13)60413-4

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free